Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01228344 · ClinicalTrials.gov registry record
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 324
- Enrollment target
NCT01228344: Completed study, sponsored by Novartis Pharmaceuticals.
NCT01228344 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 324 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01228344 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 324 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.
Interventions
- OTHER Artemether-lumefantrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2010-05-01 |
| Est. Completion | 2015-09-30 |
What the finished NCT01228344 record still lists
NCT01228344 is an observational study that tracks outcomes without assigning an intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Artemether-lumefantrine is the first listed.
NCT01228344 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01228344 about?
NCT01228344 is a clinical study titled "Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria". The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitan...
What is the current status of trial NCT01228344?
This trial is currently completed. The enrollment target is 324 participants. The study started on 2010-05-01. Estimated completion is 2015-09-30.
What interventions are being tested in trial NCT01228344?
The interventions under investigation include: Artemether-lumefantrine (OTHER).
Who is sponsoring clinical trial NCT01228344?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI